| |
We identified 54 186 patients with diabetes who started taking an angiotensinreceptor blocker during the study period. After multivariable adjustment, patients who took either telmisartan (adjusted hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.74–0.97) or valsartan (adjusted HR 0.86, 95% CI 0.77–0.95) had a lower risk of the composite outcome compared with patients who took irbesartan. In contrast, no significant difference in risk was seen between other angiotensin-receptor blockers and irbesartan. In secondary analyses, we found a reduced risk of admission to hospital for heart failure with telmisartan compared with irbesartan (adjusted HR 0.79, 95% CI 0.66– 0.96), but no significant differences in risk were seen between angiotensin-receptor blockers in our other secondary analyses.
http://www.cmaj.ca/content/early/2013/07/08/cmaj.121771
Aa«åÇáQÌXNÖÌe¿B
e~T^ÆJfT^ª@CxT^æèàLÓÉXNðº°éÆÌÅ·ªEEE
|
|
